诚信认证：
工商注册信息已核实！
快速导航
产品分类
微信二维码
Minisite
QQ号咨询
不对称合成
Ipragliflozin
| 品牌 | 厂商性质 | 产地 | 货期 |
|---|---|---|---|
| 阿拉丁 | 生产商 | 上海 | 现货 |
产品参数
| 货号 | CAS号 | 价格（元） | 操作 |
|---|---|---|---|
| I177384-100mg | 761423-87-4 | 549 | 询价 |
| I177384-10mg | 761423-87-4 | 119 | 询价 |
| I177384-1g | 761423-87-4 | 2799 | 询价 |
| I177384-25mg | 761423-87-4 | 199 | 询价 |
| I177384-500mg | 761423-87-4 | 1899 | 询价 |
产品介绍
属性
| 溶解性 | DMSO : ≥ 100 mg/mL (247.25 mM) H2O : < 0.1 mg/mL (insoluble) |
| 存贮条件 | 储存温度-20°C |
描述
| 产品介绍 | Ipragliflozin (ASP1941) is a highly potent and selective SGLT2 inhibitor with IC50 of 2.8 nM; little and NO potency for SGLT1/3/4/5/6. IC50 value: 2.8 nM Target: SGLT2 in vitro: Ipragliflozin potently and selectively inhibited human, rat, and mouse SGLT2 at nanomolar ranges and exhibited stability against intestinal glucosidases. in vivo: Ipragliflozin showed good pharmacokinetic properties following oral dosing, and dose-dependently increased urinary glucose excretion, which lasted for over 12 h in normal mice. Oral administration of ipragliflozin increased urinary glucose excretion in a dose-dependent manner, an effect which was significant at doses of 0.3 mg/kg or higher and lasted over 12 h. Single administration of ipragliflozin dose-dependently increased urinary glucose excretion, reduced blood glucose and plasma insulin levels, and improved glucose intolerance . |
| 别名 | (1S)-1,5-脱水-1-C-[3-[(1-苯并噻吩-2-基)甲基]-4-氟苯基]-D-葡糖醇 ;(1S)-1,5-Anhydro-1-C-[3-[(1-benzothiophen-2-yl)methyl]-4-fluorophenyl]-D-glucitol |
Ipragliflozin信息由上海阿拉丁生化科技股份有限公司为您提供，如您想了解更多关于Ipragliflozin报价、型号、参数等信息，欢迎来电或留言咨询。
注：该产品未在中华人民共和国食品药品监督管理部门申请医疗器械注册和备案，不可用于临床诊断或治疗等相关用途